HTA AND PRICING POLICIES IN EU AFTER THE TRANSPARENCY DIRECTIVE

Track:
HTA/Sustainability of Health Systems in Europe

Day & Time:
March 5, 4:00PM - 5:30PM

Session Number:
0104

Type:
Session

Title:
HTA AND PRICING POLICIES IN EU AFTER THE TRANSPARENCY DIRECTIVE

Chair(s):
Richard Bergstroem, MS
Director-General
EFPIA, Belgium

Description:
The EU Transparency Directive has been in force since more than 20 years. The European Commission has proposed to update the directive and to also subject HTA to the procedural rules (including timelines) of the directive. The proposal is currently under discussion in Council and the European Parliament. Regardless of the outcome of these discussions, HTA is at the core of EU policy-making on pharmaceuticals. This session will explore the latest developments of the directive and discuss how the legal framework for HTA is evolving.

Presentation(s) & Speaker(s):
HTA in Europe: Within or outside the Directive - does it make a difference?
Andrea Rappagliosi, LLM
Vice-President Market Access, Health Policy and Medical Affairs
Sanofi Pasteur MSD, France